Advertisement

Lobar Surgery for Breast Cancer

  • Mona Tan
Chapter

Abstract

Breast conservation treatment (BCT) is appropriate surgical therapy for breast malignancies where clear margins and acceptable cosmetic outcomes can be achieved. Conventionally, the goal of a ‘lumpectomy’ is the attainment of a gross concentric margin of about 10 mm, resulting in a resection pattern approximating a sphere. Such an approach neither takes into account the anatomy of the breast nor the distribution of disease. It has been shown that breast parenchyma has a lobar anatomy, and disease conforms to a pattern referred to as ‘the sick lobe’. Preoperative mapping with imaging and tumour resection respecting these anatomic and pathologic proclivities optimise excision of disease segments, as well as facilitate parenchymal closure for good cosmetic results, and can increase BCT rates when appropriately applied. These objectives form the basis of lobar surgery for breast cancer, and the technical manoeuvres which take cues from the sick lobe theory to achieve optimal treatment outcomes are discussed in this chapter.

Keywords

Multifocal multicentric breast cancer Breast conservation treatment Lobar surgery Sick lobe Cosmetic outcomes 

References

  1. 1.
    Tot T. The theory of the sick lobe and the possible consequences. Int J Surg Pathol. 2007;15(4):369–75.CrossRefPubMedGoogle Scholar
  2. 2.
    Tot T. Subgross morphology, the sick lobe hypothesis, and the success of breast conservation. Int J Br Cancer. 2011;2011:8.  https://doi.org/10.4061/2011/634021.CrossRefGoogle Scholar
  3. 3.
    Amy D, Durante E, Tot T. The lobar approach to breast ultrasound imaging and surgery. J Med Ultrason. 2015;42:331–9.CrossRefGoogle Scholar
  4. 4.
    Veronesi U, Cascinelli N, Nariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–32.CrossRefPubMedGoogle Scholar
  5. 5.
    Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomised trial comparing mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.CrossRefPubMedGoogle Scholar
  6. 6.
    Hwang ES, Lichtensztajn DY, Gomez SL, Foeble B, Clarke CA. Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. Cancer. 2013;119:1402–11.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Agarwal S, Pappas L, Neumayer L, et al. Effect of breast conservation therapy vs mastectomy on disease-specific survival for early-stage breast cancer. JAMA Surg. 2014;149(3):267–74.  https://doi.org/10.1001/jamasurg2013.3049.CrossRefPubMedGoogle Scholar
  8. 8.
    van Hezewijk M, Bastiaannet E, Putter H, et al. Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane adjuvant multinational (TEAM) trial. Radiother Oncol. 2013;108:190–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Abdulkarim BS, Cuartero J, Hanson J, Deschenes J, Lesniak D, Sabri S. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast –conserving therapy. J Clin Oncol. 2011;29:2852–8.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Keating NL, Landrum MB, Brooks JM, et al. Outcomes following local therapy for early-stage breast cancer in non-trial populations. Breast Cancer Res Treat. 2001;125(3):803–13.CrossRefGoogle Scholar
  11. 11.
    Schonberg MA, Marcantonio ER, Li DL, et al. Breast cancer among the oldest old: tumour characteristics, treatment choices and survival. J Clin Oncol. 2010;28:2038–45.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Martin MA, Meyricke R, O’Neill T, Roberts S. Breast-conserving surgery versus mastectomy for survival from breast cancer: the western Australian experience. Ann Surg Oncol. 2007;14:157–64.CrossRefPubMedGoogle Scholar
  13. 13.
    Hofvind S, Holen A, Aas T, Roman M, Sebuødegård S, Akslen LA. Women treated with breast conserving surgery do better than those with mastectomy independent of detection mode, prognostic and predictive tumour characteristics. Eur J Surg Oncol. 2015;41(10):1417–22.  https://doi.org/10.1016/j.ejso.2015.07.002.CrossRefPubMedGoogle Scholar
  14. 14.
    Brooks JM, Chrischilles EA, Landrum MB, et al. Survival implications associated with variation in mastectomy rates for early-staged breast cancer. Int J Surg Oncol. 2012;2012:9.  https://doi.org/10.1155/2012/127854.CrossRefGoogle Scholar
  15. 15.
    van der Heiden-van der Loo M, Siesling S, Wouters MWJM, van Dalen T, Rutgers EJT, Peeters PHM. The value of ipsilateral breast tumour recurrence as a quality indicator: hospital variation in the Netherlands. Ann Surg Oncol. 2015;22(Supplement 3):522–8.  https://doi.org/10.1245/s10434-015-4626-9.CrossRefGoogle Scholar
  16. 16.
    George WD. Management of early breast cancer. Langenbecks Arch Chir. 1977;345:111–3.CrossRefPubMedGoogle Scholar
  17. 17.
    Baildam AD. Oncoplastic surgery of the breast. Br J Surg. 2001;89:532–3.CrossRefGoogle Scholar
  18. 18.
    Eichler C, Kolsch M, Sauerwald A, Bach A, Gluz O, Warm M. Lumpectomy versus mastopexy–a post-surgery patient survey. Anticancer Res. 2013;33:731–6.PubMedGoogle Scholar
  19. 19.
    De Lorenzi F, Hubner G, Rotmensz N, et al. Oncological results of oncoplastic breast-conserving surgery: long term follow-up of a large series at a single institution: a matched-cohort analysis. Eur J Surg Oncol. 2015;42(1):71–7.  https://doi.org/10.1016/j.ejso.2015.08.160.CrossRefPubMedGoogle Scholar
  20. 20.
    Clough KB, Benyahi D, Nos C, Charles C, Sarfati I. Oncoplastic surgery: pushing the limits of breast-conserving surgery. Breast J. 2015;21:140–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Chatterjee A, Pyfer B, Czerniecki B, Rosenkranz K, Tchou J, Fisher C. Early postoperative outcomes in lumpectomy versus simple mastectomy. J Surg Res. 2015;198:143–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Tan M. Toward a reductionist approach to the surgical treatment of breast cancer. J Am Coll Surg. 2016;222:967.CrossRefPubMedGoogle Scholar
  23. 23.
    Rosen PP, Fracchia AA, Urban JA, Schottenfeld D, Robbins GF. “residual” mammary carcinoma following simulated partial mastectomy. Cancer. 1975;35:739–47.CrossRefPubMedGoogle Scholar
  24. 24.
    Lagios MD. Multicentricity of breast carcinoma demonstrated by routine correlated serial subgross and radiographic examination. Cancer. 1977;40:1726–34.CrossRefPubMedGoogle Scholar
  25. 25.
    Holland R, Veling SHJ, Mravunac M, Hendriks JHCL. Histologic multifocality of Tis, T1-2 breast carcinomas: implications for clinical trials of breast-conserving surgery. Cancer. 1985;56:979–90.CrossRefPubMedGoogle Scholar
  26. 26.
    Tot T, Gere M. Radiologically unifocal invasive breast carcinomas: large section histopathology correlate and impact on surgical management. J Cancer Sci Ther. 2016;8:050–4.  https://doi.org/10.4172/1948-5956.1000389.CrossRefGoogle Scholar
  27. 27.
    Iacconi C, Galman L, Zheng J, et al. Multicentric cancer detected at breast MR imaging and not ar mammography: important or not? Radiology. 2015;25:150796.Google Scholar
  28. 28.
    McLaughlin S, Mittendorf EA, Bleicher RJ, McCready DR, King TA. The 2013 society of surgical oncology Susan G Komen for the cure symposium: MRI in breast cancer: where are we now? Ann Surg Oncol. 2014;21:28–36.CrossRefPubMedGoogle Scholar
  29. 29.
    Menezes GLG, Knuttel FM, Stehouver BL, Pijnappel RM, van den Bosch MSSJ. Magnetic resonance imaging in breast cancer: a literature review and future perspectives. World J Clin Oncol. 2014;5:61–70.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Dershaw DD. Preoperative MRI. Breast J. 2016;22:141–2.CrossRefPubMedGoogle Scholar
  31. 31.
    Tan MP. An algorithm for the integration of breast magnetic resonance imaging into clinical practice. Am J Surg. 2009;197:691–4.CrossRefPubMedGoogle Scholar
  32. 32.
    Tan MP. The boomerang incision for periareolar breast malignancies. Am J Surg. 2007;194:690–3.CrossRefPubMedGoogle Scholar
  33. 33.
    Pezner RD. The oncoplastic breast surgery challenge to the local radiation boost. Int J Radiat Oncol Biol Phys. 2011;79:963–4.CrossRefPubMedGoogle Scholar
  34. 34.
    Gentilini O, Botteri E, Rotmensz N, et al. Conservative surgery in patients with multifocal/multicentric breast cancer. Breast Cancer Res Treat. 2009;113:577–83.CrossRefPubMedGoogle Scholar
  35. 35.
    Ustaalioglu BO, Bilici A, Kefeli U, et al. The importance of multifocal/multicentric tumour on the disease-free survival of breast cancer patients. Am J Clin Oncol. 2012;35:580–6.CrossRefPubMedGoogle Scholar
  36. 36.
    Lynch SP, Lei XD, Hsu LM, et al. Breast cancer multifocality and multicentricity and locoregional recurrence. Oncologist. 2013;18:1167–73.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Wolters R, Wockel A, Janni W, et al. Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicentre cohort study of 8,935 patients. Breast Cancer Res Treat. 2013;142:579–90.CrossRefPubMedGoogle Scholar
  38. 38.
    Ataseven B, Lederer B, Blohmer JU, et al. Impact of multifocal of muliticentric disease on surgery and locoregional. Distant and overall survival of 6.134 breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2014;22(4):1118–27.  https://doi.org/10.1245/s10434-014-4122-7.CrossRefPubMedGoogle Scholar
  39. 39.
    Eaton BR, Losken A, Okwan-Diodu D, et al. Local recurrence patterns in breast cancer patients treated with oncoplastic reduction mammoplasty and radiotherapy. Ann Surg Oncol. 2014;21:93–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies–improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015;26:1533–46.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Nijenhuis MV, Rutgers EJ. Conservative surgery for multifocal/multicentric breast cancer. Breast. 2015;24:S96–9.CrossRefPubMedGoogle Scholar
  42. 42.
    Jochelson MS, Lampen-Sachar K, Gibbons G, et al. Do MRI and mammography reliably identify candidates for breast conservation after neoadjuvant chemotherapy? Ann Surg Oncol. 2015;22:1490–5.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Clough KB, Gouveia PF, Benyahi D, et al. Positive margins after oncoplastic surgery for breast cancer. Ann Surg Oncol. 2015;22:4247–53.CrossRefPubMedGoogle Scholar
  44. 44.
    Dolfin G. The surgical approach to the ‘sick lobe’. In: Francescatti DS, Silverstein MJ, editors. Breast cancer: a new era in management. New York: Springer; 2014. p. 113–32.CrossRefGoogle Scholar
  45. 45.
    Silverstein MJ. Radical mastectomy to radical conservation (extreme oncoplasty): a revolutionary change. J Am Coll Surg. 2016;222:1–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Savalia NB, Silverstein MJ. Oncoplastic breast reconstruction: patient selection and surgical techniques. J Surg Oncol. 2016;113(8):875–82. doi: 10.1002/jso.24212CrossRefPubMedGoogle Scholar
  47. 47.
    Kapoor NM, Chung A, Huynh K, Giuliano AE. Preliminary results: double lumpectomies for multicentric breast cancer. Am Surg. 2012;78:1345–8.PubMedGoogle Scholar
  48. 48.
  49. 49.
    Tan MP. A novel segment classification for multifocal and multicentric breast cancer to facilitate breast-conservation treatment. Breast J. 2015;21:410–7.CrossRefPubMedGoogle Scholar
  50. 50.
    Amy D. Lobar ultrasound of the breast. In: Tot T, editor. Breast cancer. London: Springer-Verlag; 2011. p. 153–62.Google Scholar
  51. 51.
    Tot T. Diffuse invasive breast carcinoma of no special type. Virchows Arch. 2016;468:199–206.CrossRefPubMedGoogle Scholar
  52. 52.
    Balmativola D, Marchio C, Maule M, et al. Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study. Breast Cancer Res Treat. 2014;148:511–23.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Redden MH, Fuhrman GM. Neoadjuvant chemotherapy in the treatment of breast cancer. Surg Clin N Am. 2013;93:493–9.CrossRefPubMedGoogle Scholar
  54. 54.
    King TA, Morrow M. Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. Nat Rev Clin Oncol. 2015;12:335–43.  https://doi.org/10.1038/nrclinonc.2015.63.CrossRefPubMedGoogle Scholar
  55. 55.
    Golshan M, Cirrincione CT, Sikov WM, et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates. Ann Surg. 2015;262:434–9.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Bollet MA, Savignoni A, Pierga JY, et al. High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies. Br J Cancer. 2008;98:734–41.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Criscitiello C, Azim HA, Agbor-tarh D, et al. Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. Ann Oncol. 2013;24:1980–5.CrossRefPubMedGoogle Scholar
  58. 58.
    Bleicher RJ, Ruth K, Sigurdson ER, et al. Breast conservation versus mastectomy for patients with T3 primary tumours (>5 cm): a review of 5685 Medicare patients. Cancer. 2016;122:42–9.CrossRefPubMedGoogle Scholar
  59. 59.
    Garcia-Etienne CA, Tomatis M, Heil J, et al. Mastectomy trends for early-stage breast cancer: a report from the EUSOMA multi-institutional European database. Eur J Cancer. 2012;48:1947–56.CrossRefPubMedGoogle Scholar
  60. 60.
    Mahmood U, Hanlon AL, Koshy M, et al. Increasing national mastectomy rates for the treatment of early stage breast cancer. Ann Surg Oncol. 2013;20:1436–43.CrossRefPubMedGoogle Scholar
  61. 61.
    Arrington AK, Jarosek SL, Virnig BA, Haberman EB, Tuttle TM. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann Surg Oncol. 2009;16:2697–704.CrossRefPubMedGoogle Scholar
  62. 62.
    Tan MP, Sitoh NY, Sim AS. Evaluation of eligibility and utilisation of breast conservation treatment in an Asian context. Asian Pac J Cancer Prev. 2014;15:4683–8.CrossRefPubMedGoogle Scholar
  63. 63.
    Molenaar S, Oort F, Sprangers M, Rutgers E, Luiten E, Mulder J, de Haes H. Predictors of patients’ choices for breast-conserving therapy or mastectomy: a prospective study. Br J Cancer. 2004;90:2123–30.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Esbona K, Li ZH, Wilke LG. Intraoperative imprint cytology and frozen section pathology for margin assessment in breast conservation surgery: a systemic review. Ann Surg Oncol. 2012;19(10):3236–45.  https://doi.org/10.1245/s10434-012-2492-2.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Tan MP, Nadya NY, Sim AS. The value of intraoperative frozen section analysis for margin status in breast conservation surgery in a non-tertiary institution. Int J Breast Cancer. 2014;2014:7.  https://doi.org/10.1155/2014/715404.CrossRefGoogle Scholar
  66. 66.
    Jeevan R, Cromwell DA, Trivella M, Lawrence G, Kearins O, Pereira J, et al. Reoperation rates after breast conserving surgery for breast cancer among women in England: retrospective study of hospital episode statistics. BMJ. 2012;345:e4505. doi: 10.1136bmj.e4505CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Woon YY, Chan MYP. Breast conservation surgery-the surgeon factor. Breast. 2005;14:131–5.CrossRefPubMedGoogle Scholar
  68. 68.
    Chan SW, Cheung C, Chan A, Cheung PS. Surgical options for Chinese patients with early invasive breast cancer: data from the Hong Kong breast cancer registry. Asian J Surg. 2016.  https://doi.org/10.1016/j.asjsur.2016.02.003.
  69. 69.
    Yau TK, Soong IS, Sze H, et al. Trends and patterns of breast conservation treatment in Hong Kong: 1994–2007. Int J Radiat Oncol Biol Phys. 2009;74:98–103.CrossRefPubMedGoogle Scholar
  70. 70.
    Wang WV, Tan SM, Chow WL. The impact of mammographic breast cancer screening in Singapore: a comparison between screen-detected and symptomatic women. Asian Pac J Cancer Prev. 2011;12:2735–40.PubMedGoogle Scholar
  71. 71.
    Tan MP, Sitoh NY, Sitoh YY. Perspectives of cosmesis following breast conservation for multifocal and multicentric breast cancers. Int J Br Cancer. 2015;2015:9. doi: 10/1155/2015/126793Google Scholar
  72. 72.
    Vera-Badillo FE, Napoleone M, Ocana A, et al. Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014;146:235–44.CrossRefPubMedGoogle Scholar
  73. 73.
    Neri A, Marellu D, Megha T, et al. Clinical significance of multifocal and multicentric breast cancers and choice of surgical treatment: a retrospective study on a series of 1158 cases. BMC Surg. 2015;15:1.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Morrow M, Van Zee KJ. Margins in DCIS: does residual disease provide an answer? Ann Surg Oncol. 2016;23(11):3423–5.  https://doi.org/10.1245/s10434-016-5255-7.CrossRefPubMedGoogle Scholar
  75. 75.
    Marescaux J, Diana M. Inventing the future of surgery. World J Surg. 2015;39:615–22.CrossRefPubMedGoogle Scholar
  76. 76.
    Morrow M. Progress in the surgical management of breast cancer: present and future. Breast. 2015;24:s2–5.CrossRefPubMedGoogle Scholar
  77. 77.
    Jagsi R, Jiang J, Momoh AO, et al. Complications after mastectomy and immediate breast reconstruction for breast cancer. Ann Surg. 2016;263:219–27.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.MammoCareSingaporeSingapore

Personalised recommendations